Compare BNL & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNL | EWTX |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.3B |
| IPO Year | 2008 | 2021 |
| Metric | BNL | EWTX |
|---|---|---|
| Price | $20.09 | $33.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $20.22 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 3.4M | 716.1K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $454,138,000.00 | N/A |
| Revenue This Year | $7.99 | N/A |
| Revenue Next Year | $5.27 | N/A |
| P/E Ratio | $39.57 | ★ N/A |
| Revenue Growth | ★ 5.17 | N/A |
| 52 Week Low | $15.28 | $12.31 |
| 52 Week High | $19.91 | $34.11 |
| Indicator | BNL | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 66.68 | 58.82 |
| Support Level | $17.36 | $28.72 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.38 | 1.47 |
| MACD | 0.16 | 0.12 |
| Stochastic Oscillator | 99.49 | 68.87 |
Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.